Here's why the Creso Pharma (ASX:CPH) share price is surging 6% today

The cannabis and psychedelics company released a positive update today.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Creso Pharma Ltd (ASX: CPH) share price is climbing today after its Canadian subsidiary announced it has secured approval to produce more psychedelic substances.

At the time of writing, Creso Pharma shares are in the green, up 6.25% trading at 10.2 cents.

Creso Pharma is a cannabis and psychedelics company with operations in Switzerland, Canada, Colombia, Israel and Australia. In July, Creso Pharma completed the acquisition of Canadian-based psychedelics company Halucenex Life Sciences.

Back view of a man lifting hish hands high in front of hemp plants grown for cannabis.

Image source: Getty Images

What did the company announce today?

Today, Creso Pharma had some positive news for the ASX market about Halucenex Life Sciences. Halucenex has secured an amendment to its dealer licence from Health Canada.

The company said this would enable it to produce psychedelic substances including psilocybin, ketamine, LSD, salvia divinorum, harmaline, salvinorin A, and MDMA.

Halucenex also plans to start growing its own botanical psilocybin and manufacturing psilocybin. And is looking to spearhead more research and development on botanic and synthetic psilocybin.

Halucenex will forward with a clinical trial investigating the use of psilocybin to treat post-traumatic stress disorder, pending regulatory approval.

Management commentary

Halucenex CEO Bill Fleming said:

We will now begin the steps towards synthetic psilocybin manufacture and botanical psilocybin growing immediately.

Both of these initiatives have the potential to deliver a number of commercial and research and development benefits and will shape future product development, clinical trials and potential licencing agreements.

Creso Pharma share price snapshot

The Creso Pharma share price has soared 62.70% over the past 12 months. This has outpaced the S&P/ASX 200 Index (ASX: XJO) which is up 9.8% over the same period.

However, in the 2021 year to date, the company's shares are in the red by around 43%. Creso Pharma shares are also down from the monthly high of 15 cents on 8 November.

The company's shares reached a 52-week high of 25.5 cents on 11 December 2020.

The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

A man looking at his laptop and thinking.
Healthcare Shares

Is CSL a fallen ASX giant to buy in July?

Confidence has been shaken, but I think the long-term opportunity remains attractive.

Read more »

A sad looking scientist sitting and upset about a share price fall.
Healthcare Shares

This red-hot ASX healthcare share hit a speed bump. What next?

The tech company must convert innovation into profits to justify its lofty valuation.

Read more »

Two health workers taking a break.
Healthcare Shares

Top broker tips 37% upside for this exciting ASX healthcare stock

This healthcare stock is one to watch.

Read more »

A woman puts her fingers in her ears with a pained expression on her face with her eyes closed as though trying to block hearing bad news or an unpleasant loud noise.
Healthcare Shares

Cochlear shares are slipping again. Is the comeback already over?

The healthcare stock needs evidence of recovering demand before rallying further.

Read more »

A young couple sits at their kitchen table looking at documents with a laptop open in front of them.
Healthcare Shares

ResMed's $490m MatrixCare sale: What it means

ResMed announces $490 million sale of MatrixCare and future shareholder returns.

Read more »

Married elderly man and woman in love spending time together on bench on a phone, symbolising retirement.
Healthcare Shares

Summerset Group delivers Q2 update

Summerset Group saw first-half FY26 sales rise 17%, with resales up 26%.

Read more »

A guy shrugs his shoulders, not sure which is the right decision.
Healthcare Shares

Cochlear shares are flying. Is this just the start?

Up 32% in a month, but can the ASX healthcare stock reach $300 again?

Read more »

Three health professionals at a hospital smile for the camera.
Healthcare Shares

2 ASX 200 healthcare shares to buy after sector rebounds 23% in a month

The rapid rebound in ASX 200 healthcare shares has caught many investors by surprise.

Read more »